Publication Bias in Recent Meta-Analyses

Michal Kicinski

Department of Science, Hasselt University, Hasselt, Belgium

Abstract

**Introduction:** Positive results have a greater chance of being published and outcomes that are statistically significant have a greater chance of being fully reported. One consequence of research underreporting is that it may influence the sample of studies that is available for a meta-analysis. Smaller studies are often characterized by larger effects in published meta-analyses, which can be possibly explained by publication bias. We investigated the association between the statistical significance of the results and the probability of being included in recent meta-analyses.

**Methods:** For meta-analyses of clinical trials, we defined the relative risk as the ratio of the probability of including statistically significant results favoring the treatment to the probability of including other results. For meta-analyses of other studies, we defined the relative risk as the ratio of the probability of including biologically plausible statistically significant results to the probability of including other results. We applied a Bayesian selection model for meta-analyses that included at least 30 studies and were published in four major general medical journals (BMJ, JAMA, Lancet, and PLOS Medicine) between 2008 and 2012.

**Results:** We identified 49 meta-analyses. The estimate of the relative risk was greater than one in 42 meta-analyses, greater than two in 16 meta-analyses, greater than three in eight meta-analyses, and greater than five in four meta-analyses. In 10 out of 28 meta-analyses of clinical trials, there was strong evidence that statistically significant results favoring the treatment were more likely to be included. In 4 out of 19 meta-analyses of observational studies, there was strong evidence that plausible statistically significant outcomes had a higher probability of being included.

**Conclusions:** Publication bias was present in a substantial proportion of large meta-analyses that were recently published in four major medical journals.

Introduction

When some study outcomes are more likely to be published than other, the literature that is available to doctors, scientists, and policy makers provides misleading information. The tendency to decide to publish a study based on its results has been long acknowledged as a major threat to the validity of conclusions from medical research[1,2]. During the past 25 years, the phenomenon of research underreporting has been extensively investigated. It is clear that statistically significant results supporting the hypothesis of the researcher often have a greater chance of being published and fully reported[3–7].

Meta-analysis, a statistical approach to estimate a parameter of interest based on multiple studies, plays an essential role in medical research. One consequence of research underreporting is that it influences the sample of studies that is available for a meta-analysis[8,9]. This causes a bias, unless the process of study selection is modeled correctly[10]. Such modeling requires strong assumptions about the nature of the publication bias, especially when the size of a meta-analysis is not very large and when robust techniques cannot be used[11–13]. As a result, when publication bias occurs, the validity of the meta-analysis is uncertain.

It is well-known that smaller studies are often characterized by larger effects in published meta-analyses[14–16]. Publication bias is one of the possible explanations of this phenomenon[17]. Although a meta-analysis is typically preceded by an investigation of the presence of publication bias, the standard detection methods are characterized by a low power[11,18–22]. Therefore, the sample of included studies may be unrepresentative of the population of all conducted studies even when publication bias has not been detected. In this study, we investigated whether statistically significant outcomes that showed a positive effect of the treatment (in the case of clinical trials) and plausible statistically significant outcomes (in the case of observational studies and interventional studies) had a greater probability of being included in recent meta-analyses than other outcomes. We
considered all meta-analyses of aggregate data that included at least 30 effect sizes from individual studies and were published between 2008 and 2012 in four major general medical journals: BMJ, JAMA, Lancet, and PLOS Medicine. We applied a Bayesian approach, which allows estimation of a parametric function that describes the selection process[23].

**Methods**

For meta-analyses of clinical trials, we a priori decided to estimate the ratio of the probability of including statistically significant results favoring the treatment to the probability of including other results. For other meta-analyses, we a priori decided to estimate the ratio of the probability of including plausible statistically significant results to the probability of including other results. The definition of plausibility was straightforward and a priori chosen. For meta-analyses of an association between a risk factor and an undesired outcome, results showing a positive association between the absence of a risk factor and an undesired outcome, results showing a negative association were regarded as plausible. In meta-analyses of associations between alcohol consumption and cardiovascular parameters, we estimated the ratio of the probability of including not statistically significant results because both a positive and negative association is biologically plausible[24,25]. A two-sided significance level of 0.05 was assumed. Further in the article, we refer to the ratio of probabilities as the relative risk (RR).

**Identification of meta-analyses**

We used PubMed to identify meta-analyses published between 2008 and 2012 in four general medical journals (BMJ, JAMA, Lancet, and PLOS Medicine). The term ‘meta-analysis’ was required to appear in the title or the abstract. Meta-analyses that combined at least 30 estimates from individual studies were considered. Only large meta-analyses were included because a substantial sample size is required to distinguish between the effects of heterogeneity and publication bias[11,26]. We considered only meta-analyses of aggregate data because a selection model based on p-values seemed to be inappropriate to study the complicated process of study selection in individual participant data meta-analyses.

**Statistical model**

For each identified meta-analysis, we applied a hierarchical selection model[23,27]. In this approach, a weight function is incorporated in a meta-analysis to model the probability that an individual study is included. Similarly as in the case of a standard random effects meta-analysis, the conditional distribution of the observed study effects \( Y_i \) (i=1, ..., N), given the true study effect \( \alpha \) and the within-study variance \( \sigma_i^2 \), is assumed to be normal: f(\( y_i | \alpha, \sigma_i^2 \))\sim\mathrm{N}(\alpha, \sigma_i^2). The true study effect comes from a normal distribution: N(\( \mu, \tau^2 \)), where \( \mu \) is the mean effect size and \( \tau^2 \) is the between-study variance. When a selection process is present some studies may fail to enter the meta-analysis sample. To model the process of study selection, the probability that any specific study enters the sample is assumed to be multiplied by a nonnegative weight function. In this case, the observed study effects X, that enter the meta-analysis sample (j=1, ..., n, n ≤ N) have a weighted density: 

\[ p(x|\alpha, \sigma_i^2) = w(x|\alpha, \sigma_i^2)f(x|\alpha, \sigma_i^2)I(w(x|\alpha, \sigma_i^2)) \]

where w(x) is a weight function. We applied a step weight function that took two values: \( Y_1 \) for statistically significant results favoring the treatment (in the case of clinical trials) or plausible statistically significant results (in the case of other studies) and \( Y_2 \) for other results, so that the RR equaled \( \frac{Y_1}{Y_2} \).

Maximum likelihood estimation is one possible approach to fit the model described above[27,28]. We used Bayesian inference because it produces valid results when the sample size is small[29], allows a straightforward interval estimation, and examination of the sensitivity of the findings to the distribution of the random effects. Similarly to Silliman[23], we applied a diffuse uniform priors U(0,1) for the parameters of the weight function. We declared a diffuse prior N(0,1000) for the mean effect size and, following a recommendation of Gelman[30], a uniform prior for the between-study standard deviation. We used Gibbs sampling [31] to obtain samples from the posterior distribution of \( \frac{Y_1}{Y_2} \). We applied the algorithm described by Silliman, who considered a general class of hierarchical selection models[23]. In our specific case, the full conditional distributions needed by the Gibbs sampler were:

\[
\begin{align*}
\alpha_j &\sim \mathcal{N}(\mu, \tau^2), \ Y_1 \sim \text{Bernoulli}(\frac{1}{2}) \\
\mu &\sim \mathcal{N}\left(\frac{\sum_{j=1}^n \alpha_j}{n}, \frac{1000}{\tau^2+1000n}\right) \\
\tau^2 &\sim \text{IG}\left(\frac{n}{2}, \frac{1}{2}\sum_{j=1}^n (\alpha_j - \mu)^2\right) \\
Y_1 &\sim \frac{Y_1}{\prod_{j=1}^n f(x_j|\alpha_j, \sigma_j^2)} \\
Y_2 &\sim \frac{Y_2}{\prod_{j=1}^n f(x_j|\alpha_j, \sigma_j^2, \tau^2)} \\
\end{align*}
\]

where \( f(x_j|\alpha_j, \sigma_j^2) = \int w(x|\alpha, \sigma_i^2)f(x|\alpha, \sigma_i^2)dx \), \( x = (x_1, ..., x_n) \), \( \sigma = (\sigma_1, ..., \sigma_n) \), \( \Sigma = (\Sigma_1, ..., \Sigma_n) \), \( \Sigma_0 = (\Sigma_1, ..., \Sigma_n) \), and \( s \) is the number of statistically significant results favoring the treatment (in the case of meta-analyses of clinical trials) or plausible statistically significant results (in the case of meta-analysis of other studies). A burn-in of 10000 iterations was sufficient to achieve convergence for all meta-analyses. The estimates were based on the subsequent 50000 iterations.

For point estimation, we used the median of the posterior distribution of RR. For interval estimation, we used the 95% equal-tail credible interval (CI). When the posterior probability that the RR exceeded 1 was greater than 0.95, we concluded that there was strong evidence that the RR was greater than 1. An R program that was used to fit the models can be found in Appendix S1.
Quality of the statistical model

In order to evaluate whether the statistical model was suitable for the objectives of the study, we performed simulations. The settings were based on the characteristics of the meta-analyses of clinical trials included in the study (see Appendix S2). The posterior distribution provided reliable information about the size of the RR (Table 1). Although the estimate of the RR based on the median of the posterior distribution was characterized by a substantial variability and was biased in some scenarios, it gave a correct idea about the existence of a publication bias. The model tended to underestimate the RR when the mean effect size was small and overestimate the RR when the mean effect size was large. However, it was able to distinguish the RR from the mean effect size well for all simulation settings, as indicated by the quality of the interval estimates of the RR. For almost all scenarios, the lower bound of the 95% equal-tail credible interval was smaller than the assumed true value of the RR in at least 95% of the simulations. Although the upper bound was sometimes too small when the mean effect size was small, it was greater than the true RR in more than 95% of the simulations for most of the scenarios (Table 1). The performance of the model did not depend on the size of the between-study heterogeneity. The model was robust to the presence of small study effects (i.e., larger true effects in smaller studies, Table 1).

Additionally, we compared the ability of our model to detect a selection process based on the statistical significance with publication bias methods widely used in medical research: the Egger’s test[32], correlation test of Begg and Mazumdar[33], and the trim and fill method[34]. When statistically significant outcomes had a higher probability of being included, the Bayesian selection model showed much higher detection rates compared to the standard methods (Table 2). This difference was especially apparent when small study effects were absent. Furthermore, in contrast to the standard methods, the Bayesian selection model was characterized by low false positive rates, even in the presence of small-study effects (Table 2).

Sensitivity analysis

In order to investigate the robustness of the findings, two alternative models were considered. Because the conclusions drawn from a hierarchical model may be sensitive to the choice of the prior for the variance of the random effects[35], in the first model, we replaced the uniform prior for $\tau$ with a $1/\tau^2$ prior for $\tau^2$ (for an R program: see Appendix S1). In the second model, the assumption of a normal distribution of $\alpha$ was relaxed by allowing it to follow a $t$-distribution. A prior $U(2,100)$ was declared for the number of degrees of freedom. A Winbugs program that was used to fit this model can be found in Appendix S3.

Results

Identification of meta-analyses

Out of 406 articles that were identified in the initial search, 88 articles did not report meta-analyses of an association. We excluded 280 articles because they did not describe a meta-analysis including at least 30 effect sizes. Further, 14 articles did not report any results from a meta-analysis of aggregate data. Finally, four articles were excluded because they did not report the effect sizes from the individual studies and the corresponding author did not respond to a request to provide
them. Twenty reports including 49 meta-analyses were used in this study (Figure 1 and Figure 2, references: Appendix S4, raw data available at www.plosone.org).

**RR in meta-analyses of clinical trials**

We estimated the ratio of the probability of including statistically significant results favoring the treatment to the probability of including other results in 28 large meta-analyses of clinical trials that were described in nine articles published in BMJ, JAMA, Lancet, or PLOS Medicine from 2008 to 2012 (Figure 1). In 25 out of the 28 meta-analyses, the estimate of the RR was greater than 1. In 10 meta-analyses, there was strong evidence that statistically significant results favoring the treatment had a higher probability of being included than other outcomes (Figure 1). Trials that demonstrated the efficacy of adding lidocaine on prevention of pain on injection of propofol were estimated to be between 2.45 and 141 times more likely to be included in the meta-analysis than other trials (Figure 3A). Studies favoring pretreatment with lidocaine were estimated to have a between 2.21 and 61.5-fold higher probability of being included in the meta-analysis than other studies (Figure 3B). Changing the prior distribution for the between-study variance and the distribution of the true study effects had little effect on the estimates (Appendix S5).

**RR in other meta-analyses**

We identified 10 articles describing 19 meta-analyses of observational studies and one article describing two meta-analyses of interventional studies that were published in BMJ, JAMA, Lancet, or PLOS Medicine between 2008 and 2012. In four meta-analyses, there was strong evidence that plausible statistically significant results had a higher probability of being included than other outcomes (Figure 2). Studies that showed a statistically significant positive association between the C-reactive protein level and cardiovascular events were estimated to have a between 6.97 and 30.7-fold higher probability of being included in the meta-analysis than studies showing other outcomes (Figure 4A). Statistically significant results showing a positive association were estimated to be between 1.92 and 18.1 times more likely to be included in the meta-analysis on the association between child physical abuse and depressive disorders (Figure 4B). The results were robust to the choice of the prior distribution for the between-study variance and the assumption about the distribution of the true study effects (Appendix S6).
Table 2 (continued).

| RR: relative risk, the ratio of the probability of including statistically significant outcomes favoring the treatment to the probability of including other outcomes (for RR=1, all results had the same probability of being included), SSE: small study effect, $\mu$: proportion of the total variability due to heterogeneity, $\mu$: mean effect size. Proportion of meta-analyses, in which publication bias was identified, is presented. For the Bayesian selection model, publication bias was indicated when the posterior probability that the RR was larger than 1 exceeded 95%. For the Egger’s test and the rank correlation test, one-sided procedures were used with a 0.05 significance level. For the trim and fill method, publication bias was indicated when the number of missing studies estimated by the $R$ estimator in the first step of the algorithm was greater than 3[34].

doi: 10.1371/journal.pone.0081823.t002

Discussion

Clinical trials showing statistically significant results favoring the treatment and observational studies showing plausible statistically significant outcomes often had a higher probability of being included in the recent meta-analyses than studies showing other results. The magnitude of the publication bias differed greatly between the meta-analyses and was very large in some cases. For example, for a meta-analysis of the association between the C-reactive protein level and cardiovascular events, statistically significant outcomes showing a positive association were estimated to be between 6.97 and 30.7 times more likely to be included in the analyzed sample than other results.

The effect of the higher probability of including for statistically significant outcomes on the combined estimates is unknown due to a lack of information about the exact nature of the bias. However, it is clear that the fundamental assumption of a lack of systematic bias in the process of study selection was strongly violated. Consequently, the validity of a substantial proportion of the recent meta-analyses published in major general medical journals is uncertain due to the presence of a publication bias. Only in 3[36–38] out of the 14 meta-analyses, in which we found evidence that statistically significant outcomes had a higher probability to be included, the presence of a publication bias was acknowledged in the article.

The study demonstrates an application of an attractive alternative to the standard publication bias detection methods for studying a selection process based on the statistical significance in large meta-analyses. Widely used publication bias methods such as the trim and fill method[34,39], Egger’s test[32], rank correlation test[33], and their modifications[18,19,40–42] are based on funnel plot asymmetry. These approaches have two major disadvantages. First, funnel plot asymmetry may be caused by processes other than publication bias, such as between-study variability or small study effects (i.e., larger true effects in smaller studies)[17,32]. As a result, these methods may incorrectly suggest that a publication bias is present[13,22,43,44]. Second, some selection processes introduce little asymmetry to the funnel plot. As a result, widely used publication bias tests often have a low power[18,20,22]. In contrast to these methods, selection models do not rely on the funnel plot but incorporate a model for publication bias in the random effects meta-analysis. While standard approaches investigate the association between effect sizes and some measure of precision to draw conclusions about publication bias, selection models allow to directly estimate parameters that describe the selection process.

Several alternatives to the methods based on the funnel plot have been suggested. Iyengar and Greenhouse introduced selection models in meta-analysis[45]. Hedges proposed a class of selection models that incorporated between-study variance[27]. The advantage of these two frequentist methods compared to the class of Bayesian hierarchical selection models described by Silliman[23] is their computational simplicity. We chose the Bayesian approach because it produces valid conclusions when the sample size is small[29], allows a straightforward interval estimation and examination of the sensitivity of the findings to the distribution of the random effects. When a selection process based on the $p$-values is a point of interest but the weight function is difficult to specify a priori, non-parametric selection models can be used[46,47]. In this study, a parametric model was applied because the aim was to estimate a specific parametric function. Ioannidis and Trikalinos introduced a method based on a comparison of the number of expected and observed statistically significant results in a meta-analysis[48]. A major advantage of this approach is that it does not require a large sample size. An advantage of selection models compared to the method of Ioannidis and Trikalinos is that they allow to take between-study variance into account.

Different selection mechanisms have been considered. Dear and Begg developed a selection model based on the assumption that the probability of publishing can be described with a step function with discontinuities at alternate observed $p$-values[46]. Rufibach described a method that imposed a monotonicity constrained on this function[47]. The trim and fill method handles publication bias defined as the absence of studies with most extreme negative estimates[34,39]. The model of Copas and Shi assumes that the selection probability, given the size of the study, is an increasing function of the observed study effect[49]. Ioannidis and Trikalinos developed a test to investigate an excess of statistically significant findings[48]. We investigated whether statistically significant results favoring the treatment had a higher probability of being included in the meta-analyses of clinical trials. We focused on this selection process because its existence in the medical literature is well-documented by empirical studies following research from inception or submission to a regulatory authority[4,6]. In the case of other meta-analyses, we estimated the ratio of the probability of including biologically plausible statistically significant results to the probability of including other results. As demonstrated by the simulation study, our model performed well in detecting a selection process based on the statistical significance and direction of the effect. However, the power of the model to detect publication bias may be lower when a selection mechanism of a different nature occurs.

The main limitation of the study is that we focused on the largest meta-analyses. Possibly, the size of the association...
between the statistical significance of the results and the probability of including is different for small and medium meta-analyses than for the largest meta-analyses that we considered.

When publication bias is detected, an analyst can attempt to account for it[23,28,39,47,49–51]. Although the methods to conduct meta-analysis in the presence of a publication bias provide a powerful sensitivity analysis tool, their validity

---

**Figure 1. Publication bias in meta-analyses of clinical trials.** The RR is the ratio of the probability of including statistically significant results favoring the treatment to the probability of including other results. The median of the posterior distribution was used for point estimation. The interval estimate is the 95% equal-tail credible interval. P(RR>1) is the posterior probability that statistically significant results favoring the treatment had a higher chance of being included in the meta-analysis than other results.

doi: 10.1371/journal.pone.0081823.g001

---

| Reference  | Investigated association                                                                 | RR (95% CI)     | RR (95% CI)     | P(RR>1) |
|------------|------------------------------------------------------------------------------------------|-----------------|-----------------|---------|
| Bangalore, 2011 | Angiotensin receptor blockers and myocardial infarction                                 | 2.41 (0.80-10.5) | 0.881           |         |
| Bangalore, 2011 | Angiotensin receptor blockers and mortality                                                | 2.30 (0.87-8.02) | 0.901           |         |
| Bangalore, 2011 | Angiotensin receptor blockers and heart failure                                            | 1.52 (0.54-5.65) | 0.781           |         |
| Beswick, 2008 | Interventions to improve physical functioning and not living at home                      | 2.37 (0.86-6.64) | 0.950           |         |
| Beswick, 2008 | Interventions to improve physical functioning and risk of death                           | 2.70 (1.04-6.46) | 0.980           |         |
| Beswick, 2008 | Interventions to improve physical functioning and hospital admission                      | 1.48 (0.53-4.58) | 0.779           |         |
| Beswick, 2008 | Interventions to improve physical functioning and physical function                       | 1.51 (0.60-4.29) | 0.809           |         |
| Hempel, 2012 | Probiotic use and antibiotic-associated diarrhea                                            | 3.94 (1.62-9.03) | 0.999           |         |
| Jalota, 2011  | Adding lidocaine and the risk of pain on injection of propofol                            | 13.4 (2.45-141) | 0.999           |         |
| Jalota, 2011  | Pretreatment with lidocaine and the risk of pain on injection of propofol                 | 9.80 (2.21-61.5) | 0.999           |         |
| Ker, 2012     | Tranexamic acid in surgery and the risk of blood transfusion                              | 1.76 (0.66-5.84) | 0.864           |         |
| Law, 2009     | Beta blockers and coronary heart disease                                                  | 1.85 (0.78-5.16) | 0.908           |         |
| Law, 2009     | Drugs other than beta blockers and coronary heart disease                                 | 1.24 (0.58-2.73) | 0.722           |         |
| Law, 2009     | Single drug blood pressure treatment and coronary heart disease                          | 1.16 (0.54-2.57) | 0.681           |         |
| Law, 2009     | Single drug blood pressure treatment and stroke                                           | 3.54 (1.17-11.1) | 0.990           |         |
| Law, 2009     | Blood pressure decrease and coronary heart disease                                       | 0.80 (0.33-1.60) | 0.269           |         |
| Law, 2009     | Blood pressure decrease and stroke                                                       | 3.56 (1.35-9.58) | 0.995           |         |
| Leuch, 2012   | Antipsychotic drugs and relapse of schizophrenia up to three months                      | 1.87 (0.67-7.29) | 0.875           |         |
| Leuch, 2012   | Antipsychotic drugs and relapse of schizophrenia four to six months                      | 2.84 (0.96-10.5) | 0.969           |         |
| Leuch, 2012   | Antipsychotic drugs and relapse of schizophrenia                                         | 3.67 (1.30-11.1) | 0.994           |         |
| Leuch, 2012   | Antipsychotic drugs and leaving the study early due to any reason                         | 2.94 (1.01-8.54) | 0.977           |         |
| Leuch, 2012   | Antipsychotic drugs and leaving the study early due to inefficacy                         | 1.25 (0.50-3.68) | 0.691           |         |
| Leuch, 2009   | Risperidone vs 1st gen. drugs and overall symptoms of schizophrenia                       | 1.09 (0.33-3.50) | 0.573           |         |
| Leuch, 2009   | Risperidone vs 1st gen. drugs and negative symptoms of schizophrenia                     | 1.09 (0.34-3.44) | 0.571           |         |
| Tricco, 2012  | Quality improvement strategies in diabetes and glycated hemoglobin                       | 1.63 (0.88-3.09) | 0.934           |         |
| Tricco, 2012  | Quality improvement strategies in diabetes and LDL                                       | 0.29 (0.06-1.02) | 0.026           |         |
| Tricco, 2012  | Quality improvement strategies in diabetes and systolic BP                                | 1.36 (0.62-3.30) | 0.778           |         |
| Tricco, 2012  | Quality improvement strategies in diabetes and diastolic BP                              | 0.58 (0.18-1.38) | 0.116           |         |
depends on the correctness of strong and unverifiable assumptions[12]. In light of the studies on publication bias in medicine, including the one presented here, it is clear that the quality of evidence from medical research greatly benefits from policies that aim to reduce underreporting. Several measures that regulate clinical trials have been recently taken. Since 2005, the International Committee of Medical Journal Editors requires a prospective public registration of clinical trials as a condition for publication. Since 2007, the U.S. Food and Drug Administration has also required the registration of trial results. Similar initiatives are needed for observational studies in order to make a clear distinction between a predefined hypothesis testing and exploratory analysis[52]. A prospective registration of all study protocols including a detailed description of the data analysis, a requirement of consistency between the protocol and the study report, and an obligatory disclosure of the results are recommended to further improve the quality of medical literature.

Figure 2. Publication bias in meta-analyses of studies other than clinical trials. The RR is the ratio of the probability of including plausible statistically significant results to the probability of including other results. The median of the posterior distribution was used for point estimation. The interval estimate is the 95% equal-tail credible interval. P(RR>1) is the posterior probability that plausible statistically significant results had a higher chance of being included in the meta-analysis than other results.

doi: 10.1371/journal.pone.0081823.g002

| Reference         | Investigated association                                                                 | RR (95% CI)         | RR (95% CI) | P(RR>1) |
|-------------------|-------------------------------------------------------------------------------------------|---------------------|-------------|---------|
| Botteri, 2008     | Smoking and colorectal cancer incidence                                                   | 1.54 (0.64-4.52)    | 0.818       |
| Botteri, 2008     | Smoking and colorectal cancer mortality                                                   | 1.04 (0.39-2.77)    | 0.538       |
| Brien, 2011       | Alcohol consumption and high density lipoprotein cholesterol                              | 1.19 (0.45-3.28)    | 0.657       |
| Brien, 2011       | Alcohol consumption and triglycerides                                                    | 0.96 (0.24-2.83)    | 0.467       |
| Clarke, 2012      | C677T polymorphism of the MTHFR gene and coronary heart disease                          | 1.35 (0.59-3.01)    | 0.777       |
| De Boer, 2009     | Cancer survivors vs healthy people and unemployment                                       | 0.89 (0.26-2.60)    | 0.401       |
| Hemingway, 2010   | C-reactive protein level and cardiovascular events                                        | 14.4 (6.97-30.7)    | 1.000       |
| Norman, 2012      | Child physical abuse and anxiety                                                          | 1.41 (0.65-3.36)    | 0.813       |
| Norman, 2012      | Child physical abuse and depressive disorders                                             | 6.01 (1.92-18.1)    | 0.999       |
| Norman, 2012      | Child physical abuse and alcohol problem drinking                                         | 1.24 (0.46-3.87)    | 0.681       |
| Norman, 2012      | Child physical abuse and sexually transmitted infections/risky behavior                    | 1.39 (0.53-4.20)    | 0.751       |
| Norman, 2012      | Child neglect and sexually transmitted infections/risky behavior                          | 0.74 (0.22-1.88)    | 0.258       |
| Norman, 2012      | Child neglect and drug use                                                                | 1.26 (0.49-3.75)    | 0.693       |
| Palomaki, 2010    | 9p21 single-nucleotide polymorphism (2 vs 1 at-risk allele) and heart disease             | 2.68 (1.17-6.45)    | 0.990       |
| Palomaki, 2010    | 9p21 single-nucleotide polymorphism (no vs 1 at-risk allele) and heart disease           | 2.29 (1.01-5.78)    | 0.977       |
| Pan, 2011         | Depression and stroke incidence                                                          | 1.24 (0.47-3.81)    | 0.684       |
| Renehan, 2008     | BMI and postmenopausal breast cancer                                                      | 1.51 (0.59-4.64)    | 0.800       |
| Ronksley, 2011    | Alcohol consumption and coronary heart disease incidence                                  | 1.62 (0.66-4.51)    | 0.845       |
| Ronksley, 2011    | Alcohol consumption and coronary heart disease mortality                                  | 1.48 (0.59-4.42)    | 0.799       |
| Ronksley, 2011    | Alcohol consumption and all-cause mortality                                              | 0.89 (0.29-2.22)    | 0.385       |
| Ziegelbauer, 2012 | Sanitation facilities and infection with soil-transmitted helminths                       | 1.25 (0.48-3.82)    | 0.684       |
Figure 3. The posterior distribution of the RR in the meta-analyses of the associations between A) adding lidocaine and the risk of pain on injection of propofol, and B) pretreatment with lidocaine and the risk of pain on injection of propofol. The posterior distributions describe the knowledge about the RR. The higher the value of the density function, the more likely a given value of RR is in light of the prior knowledge (no prior knowledge was assumed) and the data from the meta-analysis. For both meta-analyses, there was much certainty that the RR was greater than 1, indicating that statistically significant results favoring the treatment had a greater probability of being included in the meta-analysis than other results.

doi: 10.1371/journal.pone.0081823.g003

Figure 4. The posterior distribution of the RR in the meta-analyses of the associations between A) c-reactive protein level and cardiovascular events and B) child physical abuse and depressive disorders. The posterior distributions describe the knowledge about the RR. The higher the value of the density function, the more likely a given value of RR is in light of the prior knowledge (no prior knowledge was assumed) and the data from the meta-analysis. For both meta-analyses, there was much certainty that the RR was greater than 1, indicating that plausible statistically significant results had a greater probability of being included in the meta-analysis than other results.

doi: 10.1371/journal.pone.0081823.g004
Supporting Information

Appendix S1. R code to fit the main model and the model with a modified prior for the between-study variance. (TXT)

Appendix S2. Simulation details. (PDF)

Appendix S3. Winbugs code for the model with t-distributed study-specific means. (PDF)

Appendix S4. References of meta-analyses included in the study. (PDF)

Appendix S5. Sensitivity analysis for meta-analyses of clinical trials. (PDF)

Appendix S6. Sensitivity analysis for meta-analyses of observational and interventional studies. (PDF)

Appendix S7. Raw data. (ZIP)

Author Contributions

Conceived and designed the experiments: MK. Performed the experiments: MK. Analyzed the data: MK. Contributed reagents/materials/analysis tools: MK. Wrote the manuscript: MK.

References

1. Chalmers I (1990) Underreporting research is scientific misconduct. JAMA 263: 1405-1408. doi:10.1001/jama.1990.03440100121018.
2. Dickersin K (1990) The existence of publication bias and risk factors for its occurrence. JAMA 263: 1386-1389. doi:10.1001/jama.1990.03440100970414. PubMed: 2406472.
3. Decullier E, Lhéritier V, Chaupis F (2005) Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ 331: 19-22. doi:10.1136/bmj.38488.385995.8F. PubMed: 15967761.
4. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW et al. (2008) Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PLOS ONE 3: e3091. doi:10.1371/journal.pone.0003081. PubMed: 18769481.
5. Lee K, Bacchetti P, Sim I (2008) Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis. PLOS Med 5: e191. doi:10.1371/journal.pmed.0050191.
6. Song F, Parekh-Bhurke S, Hooper L, Loke YK, Ryder J et al. (2009) Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies. BMC Med Res Methodol 9: 79. doi:10.1186/1471-2288-9-79. PubMed: 19941536.
7. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260. doi:10.1056/NEJMa0805779. PubMed: 18198864.
8. Ahmed I, Sutton AJ, Riley RD (2012) Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ: d7762. doi:10.1136/bmj.d7762. PubMed: 22247598.
9. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S et al. (2010) The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 340: c365. doi:10.1136/bmj.c365. PubMed: 20156912.
10. Kulinskaya E, Morgenthaler S, Staudte RG (2008) Meta analysis: a guide to calibrating and combining statistical evidence. John Wiley & Sons, Ltd.
11. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L et al. (2010) Assessing publication bias in meta-analyses in the presence of between-study heterogeneity. J R Stat Soc A Stat Soc 173: 575-591. doi:10.1111/j.1467-985X.2009.00629.x.
12. Sutton AJ, Song F, Gilbody SM, Abrams KR (2000) Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 9: 421-445. doi:10.1191/096228000707155524. PubMed: 11191259.
13. Terrin N, Schmid CH, Lau J, O'Kline IJ (2003) Adjusting for publication bias in the presence of heterogeneity. Stat Med 22: 2113-2126. doi:10.1002/sim.1461. PubMed: 12820277.
14. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982-989. doi:10.7326/0003-4819-135-11-200112040-00010. PubMed: 11730399.
15. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tshannen B et al. (2010) Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 341: c3515. doi:10.1136/bmj.c3515. PubMed: 20639394.
16. Zhang Z, Xu X, Ni H, Zhang Z, Xu X et al. (2013) Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care 17: R2. PubMed: 23302257.
17. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR et al. (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343: d4002. doi:10.1136/bmj.d4002. PubMed: 21784880.
18. Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Statist Med 20: 641-654. doi:10.1002/sim.698.
19. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. doi:10.1001/jama.295.6.676. PubMed: 16467236.
20. Sterne JAC, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 53: 1119-1129. doi:10.1016/S0895-4356(00)00224-0. PubMed: 11106885.
21. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893.
22. Kromrey J, Rindin-Gobbof G (2006) On knowing what we do not know: An empirical comparison of methods to detect publication bias in meta-analysis. Educational and Psychological Measurement 66: 357-373. doi:10.1177/0013164405212858.
23. Stillman N (1997) Hierarchical Selection Models With Applications in Meta Analysis. J Am Stat Assoc 92: 926-936. doi:10.1080/01621459.1997.10474047.
24. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA (2011) Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 342: d671. doi:10.1136/bmj.d671. PubMed: 21343207.
25. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA (2011) Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 342: d636. doi:10.1136/bmj.d636. PubMed: 21343206.
26. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR et al. (2009) Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol 9: 2-18. doi:10.1186/1471-2288-9-2. PubMed: 19138428.
27. Hedges L (1992) Modeling Publication Selection Effects in Meta-Analysis. Statistical Science 7: 246-255. doi:10.1214/ss/1177011364.
28. Hedges L, Vevea J (1996) Estimating Effect Size Under Publication Bias: Small Sample Properties and Robustness of a Random Effects Selection Model. Journal of Educational and Behavioral Statistics 21: 299-332. doi:10.3102/10769986021004299.
29. Gelman A, Carlin J, Stern H, Rubin D (2003) Bayesian Data Analysis, Second Edition. Chapman and Hall/CRC.
30. Gelman A (2006) Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 3: 515-533.
31. Cassella G, George E (1992) Explaining the Gibbs Sampler. The American Statistician 46: 167-174. doi: 10.1080/00031305.1992.10475878.
32. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi: 10.1136/bmj.315.7109.629. PubMed: 9310563.
33. Begg CB, Mazumdar M (1994) Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics 50: 1088-1101. doi: 10.2307/2533446. PubMed: 7786990.
34. Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463. doi:10.1111/j.0006-341X.2000.00455.x. PubMed: 10877304.
35. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR (2005) How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 24: 2401-2428. doi:10.1002/sim.2112. PubMed: 16015676.
36. Hemingway H, Phillipson P, Chen R, Fitzpatrick NK, Damant J et al. (2010) Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of 83 Studies of C-Reactive Protein in Stable Coronary Artery Disease. PLOS Med 7: e1000286. doi:10.1371/journal.pmed.1000286.
37. Jalota L, Kalira V, George L, Shi YY, Hornuss C et al. (2011) Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ 342: d1110. doi:10.1136/bmj.d1110. PubMed: 21567443.
38. Norman RE, Byambaa M, De R, Butchart A, Scott J et al. (2012) The Long-Term Health Consequences of Child Physical Abuse, Emotional Abuse, and Neglect: A Systematic Review and Meta-Analysis. PLOS Med 9: e1001349. doi:10.1371/journal.pmed.1001349. PubMed: 23209385.
39. Duval S, Tweedie R (2000) A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in MetaAnalysis. Journal of the American Statistical Association 95: 89-98. doi:10.2307/2669529.
40. Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25: 3443-3457. doi:10.1002/sim.2380. PubMed: 16345038.
41. Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ et al. (2009) Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ 339: b2981. doi:10.1136/bmj.b2981. PubMed: 19666685.
42. Rücker G, Schwarzer G, Carpenter J (2008) Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med 27: 746-763. doi:10.1002/sim.2971. PubMed: 17592851.
43. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333: 597-600. PubMed: 16974018.
44. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2007) Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 26: 4544-4562. doi:10.1002/sim.2889. PubMed: 17476644.
45. Iyengar S, Greenhouse JB (1988) Selection Models and the File Drawer Problem. Statistical Science 3: 109-117. doi:10.1214/ss/1177013012.
46. Dear K, Begg C (1992) An approach for assessing publication bias prior to performing a meta-analysis. Statistical Science 7: 237-245. doi:10.1214/ss/1177013836.
47. Ruftbach K (2011) Selection models with monotone weight functions in meta analysis. Biom J 53: 689-704. doi:10.1002/bimj.201000240. PubMed: 21567443.
48. Ioannidis JP, Trikalinos TA (2007) An exploratory test for an excess of significant findings. Clin Trials 4: 245-253. doi:10.1177/1740774507079441. PubMed: 17715249.
49. Copas JB, Shi JQ (2001) A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res 10: 251-265. doi:10.1191/096228001678227776. PubMed: 11491412.
50. Jang J, Chung Y, Kim C, Song S (2009) Bayesian meta-analysis using skewed elliptical distributions. Journal of Statistical Computation and Simulation 79: 691-704. doi:10.1080/00949650801891595.
51. Rücker G, Schwarzer G, Carpenter J, Binder H, Schumacher M (2011) Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. Biostatistics 12: 122-142. doi:10.1093/biostatistics/kxq046. PubMed: 20656692.
52. Chavers S, Fife D, Wacholtz M, Stang P, Berlin J (2011) Registration of Observational Studies: perspectives from an industry-based epidemiology group. Pharmacoepidemiol Drug Saf 20: 1009-1013. doi:10.1002/pds.2221. PubMed: 21953845.